Biotech firm touts new AI lung disease drug discovery amid third Hong Kong IPO attempt
Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis
Insilico found that its new small-molecule drug candidate, rentosertib, designed with its AI platform Chemistry42, was “generally safe and potentially effective” for treating idiopathic pulmonary fibrosis (IPF), according to its phase 2A clinical trial results published in the journal Nature Medicine on Tuesday.
IPF is a chronic disease that causes lung tissue to thicken and stiffen, leading to breathing difficulties. During a 12-week study of rentosertib, which enrolled 71 patients in China, Insilico observed an improvement in lung function for those who received a higher dose, according to the paper.
While adverse reactions related to liver toxicity occurred in some patients who were also taking another IPF drug, rentosertib met its safety objectives for the trial, Insilico said.